Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40.9Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-3.1
Enterprise Value $M19.0EPS (TTM) $-0.1Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)--Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %-3.1Quick Ratio12.7Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %-10.8Current Ratio12.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-49.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-67.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M237ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RNNKen Fisher 2014-09-30 Sold Out $0.662 - $0.875
($0.75)
$ 0.17-77%Sold Out0
RNNKen Fisher 2014-06-30 Buy $0.79 - $1.28
($0.95)
$ 0.17-82%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RNN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Jeong Tae HeumCFO 2015-01-12Sell317,272$0.91-81.32view
Ahn Chang HoDirector 2015-01-12Sell314,656$0.91-81.32view
Ahn Chang HoDirector 2014-06-12Sell136,193$0.99-82.83view
Jeong Tae HeumCFO 2013-09-09Sell71,139$0.46-63.04view
Kivel RichardDirector 2011-10-03Buy2,500$1.04-83.65view
Brandt Peter C.Director 2011-09-09Buy125,000$1.17-85.47view
Brandt Peter C.Director 2011-09-07Buy25,000$0.96-82.29view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy1,008,078$1.31-87.02view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy320,846$1.22-86.07view
McIntosh David MDirector 2009-07-30Buy5,600$0.8-78.75view

Quarterly/Annual Reports about RNN:

News about RNN:

Articles On GuruFocus.com
Weekly CEO Buys Highlight: RNN, IIG, FSC, GEO, DAN May 21 2011 
Weekly CEO Buys Highlight: GBDC, EXL, RNN, KYN, CMTL Apr 09 2011 

More From Other Websites
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Shareholder Director Nominations Nov 25 2016
REXAHN PHARMACEUTICALS, INC. Financials Nov 11 2016
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016
Rexahn reports 3Q loss Nov 07 2016
Rexahn reports 3Q loss Nov 07 2016
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 07 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 04 2016
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for... Oct 31 2016
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for... Oct 31 2016
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of... Oct 26 2016
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of... Oct 26 2016
Rexahn Pharmaceuticals Nears 52-Week Low (RNN) Oct 11 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in... Oct 10 2016
Rexahn Pharmaceuticals to Present Trial Data (RNN) Oct 06 2016
Key FDA Decisions and Trial Results Expected in October Oct 04 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in... Oct 04 2016
Rexahn Pharmaceuticals (RNN) Sees Hammer Chart Pattern: Time to Buy? Sep 26 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 20 2016
Rexahn Announces $6 Million Registered Direct Offering Sep 14 2016
REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 14 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)